We are live on
!
Find out more
KAM
Krensavage Asset Management Portfolio holdings
AUM
$256M
1-Year Est. Return
69.63%
This Fund
S&P 500
This Quarter
Est. Return
+9.39%
1 Year Est. Return
+69.63%
3 Year Est. Return
+113.28%
5 Year Est. Return
+196.5%
10 Year Est. Return
+463.27%
AUM
$189M
AUM Growth
+$8.05M
(+4.5%)
Cap. Flow
-$6.23M
Cap. Flow
% of AUM
-3.29%
Top 10 Holdings %
Top 10 Hldgs %
86.14%
Holding
16
New
2
Increased
6
Reduced
6
Closed
1
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Jazz Pharmaceuticals
JAZZ
|
+$6.96M |
| 2 |
Johnson & Johnson
JNJ
|
+$6.15M |
| 3 |
Regeneron Pharmaceuticals
REGN
|
+$2.23M |
| 4 |
Supernus Pharmaceuticals
SUPN
|
+$1.29M |
| 5 |
Vanda Pharmaceuticals
VNDA
|
+$1.18M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Exelixis
EXEL
|
+$15.4M |
| 2 |
Cardinal Health
CAH
|
+$8.16M |
| 3 |
BioNTech
BNTX
|
+$1.43M |
| 4 |
MURA
Mural Oncology
MURA
|
+$89K |
| 5 |
Enanta Pharmaceuticals
ENTA
|
+$12.9K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
United Therapeutics
UTHR
$25.8B
| $29.1M | 15.38% |
101,146
+2,918
| +3% | +$872K |
|
|
2
Cardinal Health
CAH
$53.9B
| $22.5M | 11.89% |
133,745
-55,000
| -29% | -$8.16M |
|
|
3
Exelixis
EXEL
$13.3B
| $21.8M | 11.51% |
493,526
-385,007
| -44% | -$15.4M |
|
|
4
Jazz Pharmaceuticals
JAZZ
$15.9B
| $17.5M | 9.26% |
164,816
+64,113
| +64% | +$6.96M |
|
|
5
Enanta Pharmaceuticals
ENTA
$366M
| $16M | 8.46% |
2,114,444
-2,142
| -0.1% | -$12.9K |
|
|
6
Supernus Pharmaceuticals
SUPN
$2.59B
| $14.9M | 7.88% |
472,376
+40,390
| +9% | +$1.29M |
|
7
Indivior Pharmaceuticals
INDV
$4.73B
| $14.4M | 7.6% |
974,474
+9,106
| +0.9% | +$106K |
|
8
GSK
GSK
$104B
| $10.4M | 5.52% |
271,729
-271
| -0.1% | -$10.4K |
|
|
AVDL
9
DELISTED
Avadel Pharmaceuticals
AVDL
| $8.49M | 4.49% |
958,877
+8,877
| +0.9% | +$78K |
|
|
10
BioNTech
BNTX
$22.9B
| $7.81M | 4.14% |
73,382
-14,181
| -16% | -$1.43M |
|
11
Sanofi
SNY
$103B
| $7.2M | 3.81% |
148,946
-150
| -0.1% | -$7.66K |
|
|
12
Johnson & Johnson
JNJ
$618B
| $6.11M | 3.23% |
+40,000
| New | +$6.15M |
|
13
Alkermes
ALKS
$8.22B
| $5.95M | 3.15% |
207,822
| – | – |
|
|
14
Vanda Pharmaceuticals
VNDA
$307M
| $4.84M | 2.56% |
1,024,883
+270,502
| +36% | +$1.18M |
|
|
15
Regeneron Pharmaceuticals
REGN
$78.5B
| $2.1M | 1.11% |
+4,000
| New | +$2.23M |
|
|
MURA
16
DELISTED
Mural Oncology
MURA
| – | – |
-70,263
| Closed | -$89K |
|
Similar funds
CIA
2
CIM
JFG
PIP
LRIC
GAMC
TIA
Krensavage Asset Management's Q2 2025 Portfolio in Review
As of Q2 2025, Krensavage Asset Management held 16 positions worth $189M, up 4.5% from $181M the previous quarter. Its ten largest holdings account for 86% of the portfolio.
Krensavage Asset Management withdrew a net $6.23M in Q2 2025, closing 1 position and reducing 6 holdings. Its most notable exit was Mural Oncology, an estimated $89K position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
Against the trend, Krensavage Asset Management opened a new position in Johnson & Johnson worth $6.11M.
- Krensavage Asset Management's largest Q2 2025 buy was Johnson & Johnson: 40,000 shares worth $6.11M.
- Krensavage Asset Management added most to Jazz Pharmaceuticals in Q2 2025, an estimated $6.96M increase.
- Krensavage Asset Management's biggest Q2 2025 reduction was Exelixis, cutting an estimated $15.4M.
- Krensavage Asset Management fully exited Mural Oncology in Q2 2025, selling an estimated $89K.
- Krensavage Asset Management's ten largest holdings make up 86% of its $189M portfolio in Q2 2025.
- Krensavage Asset Management opened 2 new positions and closed 1 in Q2 2025.
- Krensavage Asset Management's portfolio value rose 4.5% quarter-over-quarter to $189M.
Based on Krensavage Asset Management's 13F filing for Q2 2025, filed 15 Aug 2025.